Clinical trials: Tumor Thrombus
Thromboembolism, Cancer
Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy
This is a multicentric, phase IV study. In this study patients that are receiving an antineoplastic treatment and that have been diagnosed with venous thromboembolism will receive edoxaban as per clinical practice.
- Trial name
- EDOI (NCT04072068)
- Testing
- Edoxaban
- Where
- 18 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Venous Thromboembolism, Neoplasms
Implementing VTE Prevention in Ambulatory Cancer Care
assess effectiveness of a , compared with usual care, to assess The goal of this study is to learn if a modified clinical program can improve adherence to guideline recommendations for prevention of venous thromboembolism in…
- Trial name
- NCT07292376
- Testing
- Clinical program
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Vermont
Cancer, Venous Thromboembolism
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients.
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- CANVAS (NCT02744092)
- Testing
- Rivaroxaban, Apixaban, Edoxaban
- Where
- 151 sites in United States
- Volunteers
- 811 people
- Sponsor
- Alliance Foundation Trials, LLC.
Multiple Myeloma, Venous Thromboembolism
Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias.
Patients with newly diagnosed symptomatic multiple myeloma per IMWG criteria prior to therapy initiation are enrolled in the study.
- Trial name
- ROADMAP-MM (NCT03405571)
- Testing
- No intervention
- Where
- Greece
- Volunteers
- 800 people
- Sponsor
- University of Athens
Gynecologic Neoplasms, Venous Thromboembolism
Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
Venous thromboembolism (VTE) is an important cause of post-operative morbidity and mortality in women undergoing surgery for gynecologic malignancies.
- Conditions
- Gynecologic Neoplasms, Venous Thromboembolism, Low Molecular Weight Heparin, Argatroban
- Trial name
- NCT02935530
- Testing
- s-LMWH, LMWH, Argatroban
- Where
- China
- Volunteers
- 315 people
- Sponsor
- Huazhong University of Science and Technology
Deep Vein Thrombosis, Pulmonary Embolus, Colon Cancer
VTE Incidence After Curative Colon Cancer Surgery in an ERAS Program
Based on data on a cohort of 2,141 patients undergoing elective colonic cancer resection in an ERAS program, the incidence of postoperative thromboembolic events is estimated in patients no receiving prolonged thromboembolic…
- Trial name
- NCT06009484
- Testing
- Colon resection
- Volunteers
- 2,141 people
- Sponsor
- Nordsjaellands Hospital
Myeloproliferative Neoplasm, Splanchnic Vein Thrombosis
MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis
A registry of UK patients diagnosed to have splanchnic vein thrombosis and myeloproliferative neoplasm, including isolated mutation of JAK2V617f.
- Conditions
- Myeloproliferative Neoplasm, Splanchnic Vein Thrombosis, JAK2 V617
- Trial name
- MASCOT-R (NCT04994158)
- Testing
- Drugs, procedures
- Where
- United Kingdom
- Volunteers
- 238 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Solid Tumor, Cancer
Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis
This research study examines the safety and feasibility of aspirin with or without Simvastatin in solid tumor patients at risk for VTE (Venous Thromboembolism - or blood clots - in the arms, lets, lungs, or other part of the…
- Trial name
- NCT02285738
- Testing
- Aspirin, Simvastatin, Observation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Case Comprehensive Cancer Center
Cirrhosis, HCC - Hepatocellular Carcinoma
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
- Conditions
- Cirrhosis, HCC - Hepatocellular Carcinoma, Portal Vein Thrombosis
- Trial name
- NCT07132515
- Testing
- Enoxaparin, warfarrin, or apixaban
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Venous Thromboembolism, Pulmonary Embolism
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can occasionally be life-threatening.
- Trial name
- PHACS (NCT00876915)
- Testing
- dalteparin injection
- Where
- 7 sites in United States, Canada
- Volunteers
- 218 people
- Sponsor
- University of Rochester
Adult Cancer Patients, Right Atrial Clot
A Study of Cardiac Magnetic Resonance Imaging (CMR) for Evaluating Catheter-Associated Right Atrial Clot in People With Cancer
The researchers are doing this study to see how well cardiac magnetic resonance imaging (CMR) scans can be used to examine the properties of central venous catheter-associated right atrial clot (RA clot).
- Trial name
- NCT07549477
- Testing
- Cardiac MRI
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adenocarcinoma
Cancer-related Thromboembolic Disease
Patients with cancer are at particularly high risk of venous thromboembolism (VTE). The guidelines therefore strongly recommend thromboprophylaxis but recent surveys clearly show that oncologists are reluctant to use it because…
- Trial name
- PROSPECT (NCT02785757)
- Testing
- Thrombin Generation Assay
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Hospices Civils de Lyon
Thrombosis, Catheter
The Risk Assessment Scale for Peripherally Inserted Central Venous Catheter (PICC) Related Thrombosis in Cancer Patients
The aim of this study is to compare the accuracy and clinical predictive value of the Michigan Risk Score, Caprini Risk Assessment Model , and Maneval Scale （Chinese version）in predicting PICC-related thrombosis.
- Trial name
- NCT05977452
- Testing
- Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale
- Where
- China
- Volunteers
- 281 people
- Sponsor
- Sun Yat-sen University
Ankle Motion, Gynecologic Neoplasm
Functional Training for the Prevention of Deep Venous Thrombosis
This study aims to analyze the post-operative functional training on the prevention of deep venous thrombosis (DVT) in the patients who have accepted major surgeries for the gynecological malignancies.
- Conditions
- Ankle Motion, Gynecologic Neoplasm, Deep Venous Thrombosis, Abdominal Breathing
- Trial name
- NCT03740633
- Testing
- passive ankle pump motions on the day of surgery, active ankle pump motions and abdominal breathing training on the 1-3 day after the surgery, Regular care
- Where
- China
- Volunteers
- 398 people
- Sponsor
- Lei Li
Cancer, Venous Thromboembolism
Cancer Patients Diagnosed With Unsuspected Venous Thromboembolism (VTE) on Routine Computed Tomography (CT) Scans
This is a prospective study with the following objectives: Primary Objective: 1. To estimate the prevalence of unsuspected VTE in oncology patients on routine staging CT scans of the thorax, abdomen and pelvis.
- Trial name
- NCT00925808
- Testing
- Questionnaires
- Where
- United States
- Volunteers
- 1,187 people
- Sponsor
- M.D. Anderson Cancer Center
Localized Resectable Adult Primary Liver Cancer, Stage III Childhood Liver Cancer
Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238160
- Testing
- cisplatin, fluorouracil, adjuvant therapy
- Where
- 4 sites in Japan
- Sponsor
- Kyoto University
Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
The goal of this prospective, single-arm, multi-center Phase II clinical trial is to evaluate the clinical efficacy and safety of QL1706 combined with bevacizumab and RALOX hepatic artery infusion chemotherapy in treating liver…
- Conditions
- Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin, Bevacizumab, Type VP3/4 Portal Vein Tumor Thrombosis
- Trial name
- NCT07327788
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab, Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin (RALOX-HAIC)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Venous Thrombosis and Pulmonary Embolism
A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
This study aims to collect patient reported outcomes and assess treatment satisfaction in active cancer patients treated with rivaroxaban for VTE (venous thromboembolism).
- Trial name
- COSIMO (NCT02742623)
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- 10 sites in Australia, Belgium and 8 more
- Volunteers
- 528 people
- Sponsor
- Bayer
Deep Vein Thrombosis
Short-term Perioperative Thromboprophylaxis After Major Abdominal Surgery
Major abdominal surgery for cancer is major risk factor for thromboembolism. Patients who undergo major abdominal surgery are prone to develop venous thromboembolism, both in the early postoperative period and after hospital…
- Trial name
- NCT04709510
- Testing
- Duplex Ultrasound
- Where
- Turkey (Türkiye)
- Volunteers
- 89 people
- Sponsor
- Istanbul Medeniyet University
IRE
IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
This is a prospective, randomized, controlled, exploratory Phase II clinical study. Approximately 60 eligible patients with hepatocellular carcinoma and portal vein tumor thrombus who have received three cycles of…
- Trial name
- NCT07799922
- Testing
- IRE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital